Hussman Strategic Advisors Inc. Has $1.76 Million Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Hussman Strategic Advisors Inc. lessened its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 16.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 210,000 shares of the company's stock after selling 42,000 shares during the period. Hussman Strategic Advisors Inc. owned 0.07% of Amneal Pharmaceuticals worth $1,760,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. Jennison Associates LLC purchased a new position in Amneal Pharmaceuticals during the 1st quarter valued at about $599,000. Victory Capital Management Inc. increased its position in Amneal Pharmaceuticals by 70.9% during the 1st quarter. Victory Capital Management Inc. now owns 360,829 shares of the company's stock valued at $3,024,000 after purchasing an additional 149,699 shares during the period. CWM LLC boosted its holdings in shares of Amneal Pharmaceuticals by 275.8% in the 1st quarter. CWM LLC now owns 15,080 shares of the company's stock valued at $126,000 after buying an additional 11,067 shares in the last quarter. Xponance Inc. boosted its holdings in shares of Amneal Pharmaceuticals by 16.1% in the 1st quarter. Xponance Inc. now owns 13,183 shares of the company's stock valued at $110,000 after buying an additional 1,828 shares in the last quarter. Finally, GF Fund Management CO. LTD. boosted its holdings in shares of Amneal Pharmaceuticals by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 7,934 shares of the company's stock valued at $66,000 after buying an additional 1,428 shares in the last quarter. Hedge funds and other institutional investors own 31.82% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on AMRX shares. The Goldman Sachs Group started coverage on shares of Amneal Pharmaceuticals in a research note on Friday, June 6th. They issued a "buy" rating and a $12.00 target price for the company. Wall Street Zen downgraded shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $11.60.

Amneal Pharmaceuticals Price Performance

Shares of AMRX stock traded down $0.27 during trading hours on Friday, reaching $7.97. 1,171,049 shares of the stock were exchanged, compared to its average volume of 1,466,098. The business's fifty day moving average is $7.82 and its two-hundred day moving average is $7.96. Amneal Pharmaceuticals, Inc. has a 12-month low of $6.50 and a 12-month high of $9.48. The firm has a market capitalization of $2.50 billion, a P/E ratio of -199.20 and a beta of 1.06.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings data on Friday, May 2nd. The company reported $0.19 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.05. Amneal Pharmaceuticals had a negative net margin of 0.46% and a negative return on equity of 188.26%. The company had revenue of $695.42 million for the quarter, compared to analyst estimates of $714.78 million. As a group, equities research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.